Myeloma bone disease

Alissa Huston, G. David Roodman

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Multiple myeloma (MM) represents the second most common hematological malignancy with an incidence of 4/100,000 individuals (1). There were approximately 16,000 new cases of MM and 11,000 deaths in 2005 alone (2). MM represents a severely debilitating and essentially fatal neoplastic disease of B-cell origin. One of the major sources of morbidity and mortality for patients with MM results from osteolytic bone lesions throughout the axial skeleton which develop in over 70-80% of patients (3). These lesions are frequently associated with severe and debilitating bone pain, and pathologic fractures can occur in up to 60% of patients (4). Bataille and colleagues have demonstrated that there is a balance between bone destruction and new bone formation, as shown in bone biopsies from patients with MM (5). In more advanced disease this balance is lost, resulting in bone destruction and the development of osteolytic lesions (5). The mechanism involved is increased osteoclast activity and bone destruction which develops adjacent to MM cells, yet not in areas of normal bone marrow. Furthermore new bone formation, which would normally develop at sites of prior bone destruction, is absent with evidence of apoptotic osteoblasts (6). The lack of new bone formation explains why nuclear medicine bone scans can severely underestimate the degree of bone destruction in patients with MM. The bone lesions that develop rarely heal, even when patients are in a complete remission. As a consequence of increased bone destruction, nearly 15% of patients develop hypercalcemia. Overall, the combination of hypercalcemia, pathologic fractures, potential nerve compression, and severe bone pain frequently results in a significant degree of morbidity and mortality for patients with myeloma (7).

Original languageEnglish (US)
Title of host publicationMultiple Myeloma
Subtitle of host publicationTranslational and Emerging Therapies
PublisherCRC Press
Pages45-60
Number of pages16
ISBN (Electronic)9781420045116
ISBN (Print)9781420045109
StatePublished - Jan 1 2007
Externally publishedYes

Fingerprint

Bone Diseases
Multiple Myeloma
Bone and Bones
Osteogenesis
Spontaneous Fractures
Hypercalcemia
Morbidity
Pain
Mortality
Bone Development
Nuclear Medicine
Bone Fractures
Osteoclasts
Hematologic Neoplasms
Osteoblasts
Skeleton
B-Lymphocytes
Bone Marrow
Biopsy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Huston, A., & Roodman, G. D. (2007). Myeloma bone disease. In Multiple Myeloma: Translational and Emerging Therapies (pp. 45-60). CRC Press.

Myeloma bone disease. / Huston, Alissa; Roodman, G. David.

Multiple Myeloma: Translational and Emerging Therapies. CRC Press, 2007. p. 45-60.

Research output: Chapter in Book/Report/Conference proceedingChapter

Huston, A & Roodman, GD 2007, Myeloma bone disease. in Multiple Myeloma: Translational and Emerging Therapies. CRC Press, pp. 45-60.
Huston A, Roodman GD. Myeloma bone disease. In Multiple Myeloma: Translational and Emerging Therapies. CRC Press. 2007. p. 45-60
Huston, Alissa ; Roodman, G. David. / Myeloma bone disease. Multiple Myeloma: Translational and Emerging Therapies. CRC Press, 2007. pp. 45-60
@inbook{ba30077717974859bd81df8d08cbdc06,
title = "Myeloma bone disease",
abstract = "Multiple myeloma (MM) represents the second most common hematological malignancy with an incidence of 4/100,000 individuals (1). There were approximately 16,000 new cases of MM and 11,000 deaths in 2005 alone (2). MM represents a severely debilitating and essentially fatal neoplastic disease of B-cell origin. One of the major sources of morbidity and mortality for patients with MM results from osteolytic bone lesions throughout the axial skeleton which develop in over 70-80{\%} of patients (3). These lesions are frequently associated with severe and debilitating bone pain, and pathologic fractures can occur in up to 60{\%} of patients (4). Bataille and colleagues have demonstrated that there is a balance between bone destruction and new bone formation, as shown in bone biopsies from patients with MM (5). In more advanced disease this balance is lost, resulting in bone destruction and the development of osteolytic lesions (5). The mechanism involved is increased osteoclast activity and bone destruction which develops adjacent to MM cells, yet not in areas of normal bone marrow. Furthermore new bone formation, which would normally develop at sites of prior bone destruction, is absent with evidence of apoptotic osteoblasts (6). The lack of new bone formation explains why nuclear medicine bone scans can severely underestimate the degree of bone destruction in patients with MM. The bone lesions that develop rarely heal, even when patients are in a complete remission. As a consequence of increased bone destruction, nearly 15{\%} of patients develop hypercalcemia. Overall, the combination of hypercalcemia, pathologic fractures, potential nerve compression, and severe bone pain frequently results in a significant degree of morbidity and mortality for patients with myeloma (7).",
author = "Alissa Huston and Roodman, {G. David}",
year = "2007",
month = "1",
day = "1",
language = "English (US)",
isbn = "9781420045109",
pages = "45--60",
booktitle = "Multiple Myeloma",
publisher = "CRC Press",

}

TY - CHAP

T1 - Myeloma bone disease

AU - Huston, Alissa

AU - Roodman, G. David

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Multiple myeloma (MM) represents the second most common hematological malignancy with an incidence of 4/100,000 individuals (1). There were approximately 16,000 new cases of MM and 11,000 deaths in 2005 alone (2). MM represents a severely debilitating and essentially fatal neoplastic disease of B-cell origin. One of the major sources of morbidity and mortality for patients with MM results from osteolytic bone lesions throughout the axial skeleton which develop in over 70-80% of patients (3). These lesions are frequently associated with severe and debilitating bone pain, and pathologic fractures can occur in up to 60% of patients (4). Bataille and colleagues have demonstrated that there is a balance between bone destruction and new bone formation, as shown in bone biopsies from patients with MM (5). In more advanced disease this balance is lost, resulting in bone destruction and the development of osteolytic lesions (5). The mechanism involved is increased osteoclast activity and bone destruction which develops adjacent to MM cells, yet not in areas of normal bone marrow. Furthermore new bone formation, which would normally develop at sites of prior bone destruction, is absent with evidence of apoptotic osteoblasts (6). The lack of new bone formation explains why nuclear medicine bone scans can severely underestimate the degree of bone destruction in patients with MM. The bone lesions that develop rarely heal, even when patients are in a complete remission. As a consequence of increased bone destruction, nearly 15% of patients develop hypercalcemia. Overall, the combination of hypercalcemia, pathologic fractures, potential nerve compression, and severe bone pain frequently results in a significant degree of morbidity and mortality for patients with myeloma (7).

AB - Multiple myeloma (MM) represents the second most common hematological malignancy with an incidence of 4/100,000 individuals (1). There were approximately 16,000 new cases of MM and 11,000 deaths in 2005 alone (2). MM represents a severely debilitating and essentially fatal neoplastic disease of B-cell origin. One of the major sources of morbidity and mortality for patients with MM results from osteolytic bone lesions throughout the axial skeleton which develop in over 70-80% of patients (3). These lesions are frequently associated with severe and debilitating bone pain, and pathologic fractures can occur in up to 60% of patients (4). Bataille and colleagues have demonstrated that there is a balance between bone destruction and new bone formation, as shown in bone biopsies from patients with MM (5). In more advanced disease this balance is lost, resulting in bone destruction and the development of osteolytic lesions (5). The mechanism involved is increased osteoclast activity and bone destruction which develops adjacent to MM cells, yet not in areas of normal bone marrow. Furthermore new bone formation, which would normally develop at sites of prior bone destruction, is absent with evidence of apoptotic osteoblasts (6). The lack of new bone formation explains why nuclear medicine bone scans can severely underestimate the degree of bone destruction in patients with MM. The bone lesions that develop rarely heal, even when patients are in a complete remission. As a consequence of increased bone destruction, nearly 15% of patients develop hypercalcemia. Overall, the combination of hypercalcemia, pathologic fractures, potential nerve compression, and severe bone pain frequently results in a significant degree of morbidity and mortality for patients with myeloma (7).

UR - http://www.scopus.com/inward/record.url?scp=84889397427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889397427&partnerID=8YFLogxK

M3 - Chapter

SN - 9781420045109

SP - 45

EP - 60

BT - Multiple Myeloma

PB - CRC Press

ER -